TrialNature medicine2024

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Bram De Laere et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.